Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease

Data indicated a trend toward reduced incidence of vaso-occlusive crises over 52 weeks and increased hemoglobin response at 24 weeks compared with placebo Results to be confirmed in the phase 3 component of the HIBISCUS trial PLAINSBORO, N.J., Dec. 7, 2024 /PRNewswire/ — Novo Nordisk…